CAPITOL COUNSEL LLC for BIOTECHNOLOGY INNOVATION ORGANIZATION (FORMERLY BIOTECHNOLOGY INDUSTRY ORG.)
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Legislative and regulatory issues affecting innovation, including vaccines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM LEONARD CARASSO | — |
| SHANNON FINLEY | — |
| ANN JABLON | — |
| DAVID OLANDER | — |
Trade (domestic/foreign) TRD
Issues related to tariffs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHANNON FINLEY | — |
| JOHN MARTIN | — |
Budget/Appropriations BUD
Items related to USDA, FDA, genetic engineering, and regulations associated with biotechnology in the Agriculture/Rural Development/Food and Drug Administration proposed Appropriation measures for FY 2027 (House/Senate).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH EANNELLO | — |
Health Issues HCR
Public health issues impacting patient access to treatments. Updates and reforms to regulation of treatment development and research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY CARROLL | — |
| SHANNON FINLEY | — |
| LUKE HATZIS | — |
| ANN JABLON | — |
| JOHN MARTIN | — |
| KAREN STONE | — |
Medicare/Medicaid MMM
Medicare Part B coverage and reimbursement issues for biotechnology treatments and issues related to the Medicare Part D coverage, including issues found in H.R. 1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY CARROLL | — |
| JOSEPH EANNELLO | — |
| SHANNON FINLEY | — |
| LUKE HATZIS | — |
| ANN JABLON | — |
| JOHN MARTIN | — |
| CHARLES PATRICK MICHAELS | — |
| KAREN STONE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.